Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy

Clinical Hemorheology and Microcirculation

Volumn 22, Issue 2, 2000, Pages 107-130

  Von Tempelhoff, Georg Friedrich ^a   Nieman, Frank ^a   Heilmann, Lothar ^a   Hommel, Gerhard ^b  

^a Gesundheits und Pflegezentrum Russelsheim   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; FIBRINOGEN; HEMOGLOBIN; OXYGEN;

ANTICOAGULATION; ARTICLE; BLOOD FLOW; BLOOD RHEOLOGY; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ERYTHROCYTE AGGREGATION; FEMALE; GYNECOLOGIC CANCER; HEMATOCRIT; HUMAN; HYPERVISCOSITY SYNDROME; HYPOXIA; LEUKOCYTE; MAJOR CLINICAL STUDY; METASTASIS; MICROCIRCULATION; OVARY CANCER; PLASMA VISCOSITY; PREOPERATIVE PERIOD; PROGNOSIS; RISK FACTOR; THROMBOCYTE; THROMBOSIS; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BLOOD VISCOSITY; BREAST NEOPLASMS; CARCINOMA; CELL HYPOXIA; COHORT STUDIES; DISEASE PROGRESSION; ERYTHROCYTE AGGREGATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; GERMANY; HEMATOCRIT; HEMORHEOLOGY; HUMANS; LIFE TABLES; MICROCIRCULATION; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOPHILIA; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS; VENOUS THROMBOSIS;

EID: 0033994407     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. F.R. Rickles, M. Levine, R.L. Edwards, T.E. Moritz and L.R. Zacharski, Abnormalities of blood coagulation in patients with cancer, in: Thrombosis an Update, G.G.N. Semen, G.F. Gensini, R. Abbate and D. Prisco, eds, Scientific Press, 1992, pp. 241-260.
2. L. Dintenfass, Criteria and values in diagnosis and treatment and prevention of metastasis in neoplastic diseases, in: Rheology of Blood in Diagnostic and Preventive Medicine, L Dintenfass, ed., Boston Butterworth and co. Ltd., London, 1976, pp. 137-162.
3. B. Miller and L. Heilmann, Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment, Cancer 62 (1988), 350-354.
4. G.-F. von Tempelhoff, F. Niemann, D. Schneider, C.P. Kirkpatrick, G. Hommel and L. Heilmann, Blood rheology during chemotherapy in patients with ovarian cancer, Thromb. Res. 90 (1998), 73-82.
5. G.-F. von Tempelhoff and L. Heilmann, Thrombosis and hemorheology in patients with breast cancer and adjuvant chemotherapy, Clin. Hemorheol. 15 (1995), 311-323.
6. G.-F. von Tempelhoff, L. Heilmann, G. Hommel, D. Schneider, F. Niemann and H. Zöller, Hyperviscosity syndrome in ovarian malignancy, Cancer 82 (1998), 1104-1111.
7. G.-F. von Tempelhoff, Changes of hemorheology and clotting in different gynecological malignancies, Clin. Hemorheol. 15 (1995), 261-262.
8. J.J. Walsh, J. Bonnar and F. W. Wright, A study of pulmonary embolism and deep vein thrombosis after major gynecologic surgery using labelled fibrinogen phlebography and lung scanning, J. Obstet. Gynecol. 81 (1984), 311-316.
9. P.C. Clahsen, J. H. Cornelis, J.P.J. van der Velde, J.-L- Floiras and F.Y. Mignolet, Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cooperative Group Study, J. Clin. Oncol. 12 (1994), 1266-1271.
10. D.L. Clarke-Pearson, E. DeLong, I.S. Synan, J.T. Soper, W.T. Creasman and R.E. Colemann, A controlled trial of two low-dose-heparin regimens for the prevention of postoperative deep vein thrombosis, Obstet. Gynecol. 75 (1990), 683-689.
11. D.L. Clarke-Pearson, E.R. Delong, I.S. Synan, R.E. Coleman and W.T. Creaseman, Variables associated with postoperative deep venous thrombosis: A prospective study of 411 gynecology patients and creation of a prognostic model, Obster. Gynecol. 69 (1987), 146-150.
12. L. Heilmann, G.-F. von Tempelhoff, B. Herrie, B. Hojnacki, D. Schneider, H.C.H. Michaelis and H. Wolf, Low-dose heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynäkologischen Onkologie, Geburtshilfe und Frauenheilkunde 57 (1997), 1-6.
13. S.Z. Goldhaber, Epidemiology of pulmonary embolism and deep vein thrombosis, in: Haemostasis and Thrombosis, A.L. Bloom, Ch.D. Forbes, D.P. Thomas and E.G.D. Tuddenham, eds, Churchill, Livingstone, 1994, pp. 1327-1333.
14. W. Vasigara-Singh, S. Subramaniam, S. Shyama, M. Jagade Esan and C.S. Shyamala-Devi, Changes in erythrocyte membrane lipids in breast cancer patients after radiotherapy and chemotherapy, Chemotherapy 42 (1996), 65-70.
15. H. Chen, W. Yunpeng, C. Shaoxi and L. Mian, A research on rheological properties of erythrocyte of lung cancer patients, Clin. Hemorheol. 16 (1996), 135-141.
16. L. Dintenfass, Hemorheology of cancer metastasis - An example of malignant melanoma, survival times and abnormality of blood viscosity factors, Clin. Hemorheol. 2 (1982), 259-271.
17. A.P. Grigg, J. Allardice, I.L. Smith, W. Murray, D. Horsfall and D. Parkin, Hyperviscosity syndrome in disseminated breast adenocarcinoma, Pathology 26 (1994), 65-68.
18. M.M. Khan, R.R. Puniyani, N.G. Huilgol, M.A. Hussain and G.G. Ranade, Hemorheological profiles in cancer patients, Clin. Hemorheol. 15 (1995), 37-44.
19. F. Laffargue, J.F. Brun, P. Boulet, A. Elbouhmadi and A. Orsetti, Blood rheology in ovarian cancer, Clin. Hemorheol. 15 (1995), 550 abstract.
20. G.D.O. Lowe, Rheological influences on thrombosis, Baill Clin. Haematol. 7 (1994), 573-589.
21. M.W. Rampling, M.W. Whittingstall and O. Linderkamp, The effects of fibrinogen and its plasmin degradation products on the rheology of erythrocyte suspension, Clin. Hemorheol. 4 (1984), 533-541.
22. L. Weiss, Biochemical interactions of cancer cells with the microvasculature during hematogenous metastasis, Cancer and Metastasis Reviews 11 (1992), 227-235.
23. M. Höckel, K. Schlenger, B. Aral, M. Mitze, U. Scheffer and P. Vaupel, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Research 56 (1996), 4509-4515.
24. B.C. Liang, Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines, J. Neurol. Oncol. 29 (1996), 149-155.
25. W.V. Humphreys, A. Walker and D. Charlesworth, Altered viscosity and yield stress in patients with abdominal malignancy: Relationship to deep venous thrombosis, Br. J. Surg. 63 (1976), 559-561.
26. F. Pettersson, Annual report on the results of treatment in gynecological cancer - International Federation of Gynecology and Obstetrics, 1994, Vol. 22, Stockholm, Sweden, 1994.
27. M. Kaufmann, Current and new concepts in the systemic adjuvant treatment of breast cancer, Onkologie 16 (1993), 304-308.
28. International Committee for Standardization in Haematology, Guidelines for measurement of blood viscosity and erythrocyte deformability, Clin. Hemorheol. 6 (1986), 439-453.
29. H. Schmid-Schoenbein, H. Volger, P. Teitel, H. Kiesewetter, U. Dauer and L. Heilmann, New hemorheological techniques for routine laboratory, Clin. Hemorheol. 2 (1982), 93-97.
30. F. Jung, H. Kieseweter, H.G. Roggenkamp, H.P. Nüttgens and E.B. Ringelstein, Bestimmung der Referenzbereiche rheologischer Parameter: Studie an 653 zufallig ausgewählten Probanden im Kreis Aachen, Klin. Wochenschr. 64 (1986), 375-381.
31. A. Clauss, Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens, Acta Haematologica 17 (1957), 237-240.
32. F. Jung, H.G. Roggenkamp, R. Schneider and H. Kiesewetter, The capillary tube plasma viscosimeter, a new instrument for the measurement of the plasma viscosity, Biomed. Tech. 27 (1983), 249-252.
33. H.B. Wheeler and F.A. Anderson, Diagnostic methods for deep vein thrombosis, Haemostasis 25 (1995), 6-26.
34. F.P. Pineo and R.D. Hull, Classical anticoagulant therapy for venous thromboembolism, Prog. in Cardiovasc. Diseases 37 (1994), 59-70.
35. D.R. Cox, Regression models and life - tables, J. R. Stat. Soc. 34 (1972), 187-220.
36. E.L. Kaplan and P. Meier, Non-parametric estimations from incomplete observations, J. Am. Stat. Assoc. 53 (1958), 457-481.
37. W.P. Patterson, C.W. Caldwell and D.C. Doll, Hyperviscosity syndromes and coagulopathies, Sem. Oncol. 17 (1990), 210-216.
38. J. Contrino, G. Hair, D.L. Kreutzer and F.R. Rickles, In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease, Nat. Med. 2 (1996), 209-215.
39. L.R. Zacharski, V.A. Memoli, D.L. Omstein, S.M. Rousseau, W. Kisiel and B.J. Kudryk, Tumor cell procoagulant and urokinase expression in carcinoma of the ovary, J. Natl. Cancer. Inst. 85 (1993), 1225-1230.
40. M.M. Moradi, L.F. Carson, B. Weinberg, A.F. Haney, L.B. Twiggs and S. Ramakrishnan, Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor alpha in patients with ovarian epithelial cancer, Cancer 72 (1993), 2433-2440.
41. N. Semeraro, P. Montemurro, M. Conese, D. Giordano, M. Stella, A. Restaino et al., Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies, Int. J. Cancer 45 (1990), 251-254.
42. A. Gadducci, R. Marrai, U. Baicchi, O. Gagetti, V. Facchini and A.R. Genazzani, Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer, Gynecologic Oncology 61 (1996), 215-217.
43. S.K. Khoo, D.B. Rylatt and P. Parsons, Serial D-dimer levels in the assessment of tumor - mass and clinical outcome in ovarian cancer, Gynecol. Oncol. 29 (1988), 188-198.
44. G.-F. von Tempelhoff, M. Dietrich, F. Niemann, D. Schneider, G. Hommel and L. Heilmann, Blood coagulation and thrombosis in patients with ovarian malignancy, Thromb. Haemost. 77 (1997), 456-461.
45. G.-F. von Tempelhoff, M. Dietrich, G. Hommel and L. Heilmann, Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer, J. Clin, Oncol. 14 (1996), 2560-2568.
46. H.F. van Breugel, P.G. de Groot, R.M. Heethaar and J.J. Sixma, Role of plasma viscosity in platelet adhesion, Blood 80 (1992), 953-959.
47. C.E. Mercke, Anemia in patients with solid tumours and the role of erythrocyte deformability, Br. J. Cancer 44 (1981), 425-432.
48. D.P. Thomas, Pathogenesis of venous thrombosis, in: Hemostasis and Thrombosis, R.W. Colman, J. Hirsh, V.J. Marder and E.W. Salzman, eds, J.B. Lippincott, Philadelphia, Toronto, 1982, pp. 820-830.
49. 2 tension measurements, Cancer Research 51 (1991), 3316-3322.
50. A. Obermair, A. Handisurya, A. Kaider, P. Sevelda, H. Kölbi and G. Gitsch, The relation of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients, Cancer 83 (1998), 726-731.
51. A.K. Kakkar, A.R. Hedges, R.C.N. Williamson and V.V. Kakkar, Perioperative heparin therapy inhibits late death from metastatic cancer, Int. J. Oncol. 6 (1995), 885-888.
52. B. Lebeau, C. Chastang, J.-M. Brechot, F. Capron, B. Dautzenberg, C. Delaisements, M. Momet, J. Brun, J.-P. Hurdebourcq and E. Lemarie, Subcutaneous heparin treatment increases survival in small cell lung cancer, Cancer 74 (1994), 38-45.
53. G.-F. von Tempelhoff, D. Schneider, G. Hommel, K. Pollow and L. Heilmann, Langzeitmortalität bei 324 gynäkologischen Malignompatientinnen in Abhängigkeit von der peroperativen Thromboseprophylaxe - Eine prospektive doppelblind randomisierte Erhebung, in: Onkologie und Hamostasesystem, F.R. Matthias and H. Rasche, eds, Schattauer, Basel, Grenzch, Whylen, 1999, pp. 269-282.
54. A.W.A. Lensing, M.H. Prins, B.L. Davidson and J. Hirsh, Treatment of deep vein thrombosis with low-molecular-weight heparins, A meta-analysis, Arch. Int. Med. 155 (1995), 601-607.
55. S. Siragusa, B. Cosmi, F. Piovella, J. Hirsh and J.S. Ginsburg, Low-molecular-weight hepanns and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis, Amer. J. Med. 100 (1996), 269-277.
56. G.C. Jayson and J.T. Gallagher, Heparin oligosacharides: inhibitors of the biological activity of bFGF on Caco-2 cells, Brit. J. Cancer 75 (1997), 9-16.
57. K. Norrby, Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically, Haemostasis 23(Suppl. 1) (1993), 141-149.
58. L.R. Zacharski and D.L. Ornstein, Heparin and cancer, Thrombos. Haemost. 80 (1998), 10-23.
59. A.K. Kakkar and R.C.N. Williamsen, Prevention of venous thromboembolism in cancer using low-molecular-weight heparin, Haemostasis 27(Suppl.) (1997), 32-37.